Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In the present study, we aim to investigate the effect of buprenorphine on neuroinflammation in patients with complex regional pain syndrome, using [11C]-(R)-PK11195 PET.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with CRPS Type I | Patients diagnosed with Complex Regional Pain Syndrome Type I who are anticipated to recieve a 8 weeks regime of buprenorphine as a part of routine medical care. -drug name: norspan patch 5~20 mcg dosage form: patch frequency: every weeks duration: 8 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Buprenorphine | Drug | 5~20 mcg |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in neuroinflammation | [11C]-(R)-PK11195 PET distribution volume ratio (DVR) | baseline, 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Morphine equivalent | narcotic analgesic dosage | baseline, 8 weeks |
| Physical test(1) | blood test | baseline, 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients diagnosed with complex regional pain syndrome Type I (Budapest Criteria)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Soo-Hee Choi, MD,PhD | Contact | +82 2-2072-2302 | soohchoi@snu.ac.kr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Recruiting | Seoul | Jongno-gu | 03080 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020918 | Complex Regional Pain Syndromes |
| ID | Term |
|---|---|
| D001342 | Autonomic Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002047 | Buprenorphine |
| ID | Term |
|---|---|
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
| Physical test(2) | urine test | baseline, 8 weeks |
| Physical test(3) | Electrocardiogram(ECG) test (pulse rate) | baseline, 8 weeks |
| Physical test(4) | pulse measurement | baseline, 8 weeks |
| Physical test(5) | blood pressure measurement | baseline, 8 weeks |
| Self-reported questionnaire(1) | Beck Depression Index(BDI)/ total score: 0~63, The higher the score, the more depressed | baseline, 8 weeks |
| Self-reported questionnaire(2) | Beck Anxiety Index(BAI)/ total score: 0~63, The higher the score, the more anxiety | baseline, 8 weeks |
| Self-reported questionnaire(3) | Short Form McGill Pain Questionnaire(SF-MPQ)/ 'a' subscale score: 0~45, The higher the score, the more painful/ 'b' subscale score, 0~10, The higher the score, the more painful/ 'c' subscale score, 0~5, The higher the score, the more painful | baseline, 8 weeks |
| Self-reported questionnaire(4) | Pain Catastrophizing Scale/ total score: 0~52, The higher the score, the more pain Catastrophizing | baseline, 8 weeks |
| D006572 |
| Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |